<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002242" GROUP_ID="INFECTN" ID="622999112419245647" MERGED_FROM="" MODIFIED="2012-01-17 11:56:44 +0100" MODIFIED_BY="Anne-Marie Stephani" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2012-01-17 10:45:40 +0000" MODIFIED_BY="Anne-Marie Stephani">
<TITLE>Antibiotic treatment for travellers' diarrhoea</TITLE>
<CONTACT>
<PERSON ID="14290" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Guy</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>de Bruyn</LAST_NAME>
<SUFFIX/>
<POSITION>Project Director</POSITION>
<EMAIL_1>debruyng@phru.co.za</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Perinatal HIV Research Unit</DEPARTMENT>
<ORGANISATION>Wits Health Consortium</ORGANISATION>
<ADDRESS_1>PO Box 114</ADDRESS_1>
<ADDRESS_2>Diepkloof</ADDRESS_2>
<CITY>Johannesburg</CITY>
<ZIP>1864</ZIP>
<REGION>Guateng</REGION>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 11 989 9720</PHONE_1>
<PHONE_2/>
<FAX_1>+27 11 989 9762</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-01-17 10:45:40 +0000" MODIFIED_BY="Anne-Marie Stephani">
<PERSON ID="14290" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Guy</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>de Bruyn</LAST_NAME>
<SUFFIX/>
<POSITION>Project Director</POSITION>
<EMAIL_1>debruyng@phru.co.za</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Perinatal HIV Research Unit</DEPARTMENT>
<ORGANISATION>Wits Health Consortium</ORGANISATION>
<ADDRESS_1>PO Box 114</ADDRESS_1>
<ADDRESS_2>Diepkloof</ADDRESS_2>
<CITY>Johannesburg</CITY>
<ZIP>1864</ZIP>
<REGION>Guateng</REGION>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 11 989 9720</PHONE_1>
<PHONE_2/>
<FAX_1>+27 11 989 9762</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14300" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Seokyung</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hahn</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor of Medical Statistics</POSITION>
<EMAIL_1>hahns@snu.ac.kr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+82 10 8584 7659</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>Seoul National University College of Medicine</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2>28 Yongon-dong Chongno-gu</ADDRESS_2>
<CITY>Seoul</CITY>
<ZIP>110-744</ZIP>
<REGION/>
<COUNTRY CODE="KR">Korea, South</COUNTRY>
<PHONE_1>+82 2 740 8911</PHONE_1>
<PHONE_2/>
<FAX_1>+82 2 766 8172</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8997" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alastair</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Borwick</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>aborwick@xtra.co.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Anne Street Medical Centre</DEPARTMENT>
<ORGANISATION/>
<ADDRESS_1>29 Anne Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Devonport</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>+64 9 4453483</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-09-29 16:26:17 +0100" MODIFIED_BY="Harriet MacLehose">
<UP_TO_DATE>
<DATE DAY="21" MONTH="5" YEAR="2000"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="9" MONTH="9" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2012-01-05 10:03:04 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-05 10:03:04 +0000" MODIFIED_BY="Anne-Marie Stephani">
<DATE DAY="5" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>The CIDG is piloting a new classification system for reviews. The classification for this has now been added; description included in "Published notes" section of review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-01-05 10:01:41 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-05 10:01:41 +0000" MODIFIED_BY="Anne-Marie Stephani">
<DATE DAY="5" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format with minor editing.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-04 08:06:10 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="9" YEAR="2003"/>
<DESCRIPTION>
<P>New studies found but not yet included or excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Liverpool School of Tropical Medicine</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-01-17 10:51:49 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-01-17 10:47:28 +0000" MODIFIED_BY="Anne-Marie Stephani">
<TITLE>Antibiotic treatment reduces duration and severity of travellers' diarrhoea.</TITLE>
<SUMMARY_BODY MODIFIED="2012-01-17 10:47:28 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>Using a pilot system we have categorised this review as: Current question - update pending. (See "Published notes" section for an explanation).</P>
<P>Diarrhoea is a common problem for travellers, particularly travellers going from developed to less developed nations. The illness is frequently caused by a bacterial infection. Although the illness is unlikely to result in death, diarrhoea can disrupt travel plans and lead to severe or incapacitating symptoms. The review showed that antibiotic treatment shortens the duration and severity of diarrhoea. Persons taking antibiotics reported more side effects, but most side effects were minor, or resolved on stopping the antibiotic.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-01-17 10:47:34 +0000" MODIFIED_BY="Anne-Marie Stephani">
<ABS_BACKGROUND MODIFIED="2012-01-17 10:47:34 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>Using a pilot system we have categorised this review as: Current question - update pending (See "Published notes" section for an explanation). </P>
<P>Traveller's diarrhoea is a syndrome frequently encountered in persons crossing an international boundary. Diarrhoea can lead to significant discomfort and interference with travel plans. Bacterial pathogens are a frequent cause of this syndrome. Several antibiotics have been tested for efficacy in reducing the duration and severity of the illness.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The aims of this review were to assess the effects of antibiotics on traveller's diarrhoea in relation to duration of illness, severity of illness, and adverse effects of medications.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The Cochrane Collaboration Trials Register, MEDLINE, and EMBASE were searched. Additional trials were identified by hand searching. Content experts were contacted.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All trials in any language in which travellers older than 5 years were randomly allocated to treatment for acute non-bloody diarrhoea with antibiotics and where the causative organism is not known at allocation.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers assessed trial quality and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Twenty published studies met inclusion and quality criteria for inclusion. Twelve studies were placebo-controlled. </P>
<P>A meta-analysis for the primary outcome was not feasible. All of the 10 trials reported a significant reduction in duration of diarrhoea in participants treated with antibiotics compared with placebo.</P>
<P>Data from two trials demonstrated a small reduction for antibiotic treated patients in the number of unformed stools passed per each 24 hour period from randomisation up to 72 hours. </P>
<P>Data from six trials demonstrated a greater number of participants being cured of diarrhoea by 72 hours (odds ratio 5.90, 95% confidence interval 4.06 to 8.57).</P>
<P>Data regarding side effects were available from five trials. There was wide variation in the prevalence of side effects reported in different trials. Persons taking antibiotics experienced more side effects than those taking placebo (odds ratio 2.37, 95% confidence interval 1.50 to 3.75).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Antibiotic treatment is associated with shorter duration of diarrhoea but higher incidence of side-effects. Trials generally do not report duration of post-treatment diarrhoea using time-to-event analyses, and should do. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-04 08:07:45 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-10-04 08:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>Travellers' diarrhoea is an acute syndrome occurring in people who have crossed a national boundary and who experience watery or unformed bowel motions which are passed more frequently than usual, sometimes accompanied by nausea, vomiting, abdominal pain or cramping. Recovery within five days is normal, although in about 10% of cases symptoms will persist beyond seven days (<LINK REF="REF-DuPont-1993" TYPE="REFERENCE">DuPont 1993</LINK>, <LINK REF="REF-Farthing-1992" TYPE="REFERENCE">Farthing 1992</LINK>). The syndrome is most commonly caused by intestinal bacteria known as enterotoxigenic Escherichia coli (ETEC), although other bacteria including Campylobacter, Shigella, and Salmonella species have all been frequently incriminated (<LINK REF="REF-Black-1986" TYPE="REFERENCE">Black 1986</LINK>, <LINK REF="REF-Gorbach-1975" TYPE="REFERENCE">Gorbach 1975</LINK>, <LINK REF="STD-Taylor-1991" TYPE="STUDY">Taylor 1991</LINK>). Travellers' diarrhoea lasting for 14 days or more is sometimes termed "persistent diarrhoea" and is considered separately as the causes and management differ from the usual travellers' illness. Some 10% of travellers with diarrhoea develop dysentery, defined as diarrhoea mixed with visible blood, indicating a potentially serious condition which differs from travellers' diarrhoea and warrants separate investigation and management. Mortality is rare in simple travellers' diarrhoea although the condition is potentially serious in the very young and the elderly, who may not tolerate fluid loss, as well as in children and younger adults. Those with an impaired immune response, reduced gastric acidity, and some forms of heart disease may also be considered at risk of more severe effects from travellers' diarrhoea (<LINK REF="REF-BSSI-1996" TYPE="REFERENCE">BSSI 1996</LINK>).</P>
<P>The magnitude of the problem is considerable. With the advent of modern air travel, between 1950 and 1990 there was an increase from approximately 25 million to 425 million persons travelling worldwide (<LINK REF="REF-Hundt-1996" TYPE="REFERENCE">Hundt 1996</LINK>). Travellers' diarrhoea has been commonly reported to occur in 30-60% of travellers to developing countries, in contrast to reported incidence rates of 5% or less in travellers to Europe and North America (<LINK REF="REF-Cartwright-1997" TYPE="REFERENCE">Cartwright 1997</LINK>).</P>
<P>The incidence of the syndrome appears to vary according to the itinerary, to the season in which travel occurs, and to factors surrounding eating behaviour and style of travel, with the younger adult more at risk than the middle-aged (<LINK REF="REF-Steffen-1983" TYPE="REFERENCE">Steffen 1983</LINK>, <LINK REF="STD-Mattila-1993" TYPE="STUDY">Mattila 1993</LINK>). Nevertheless, diarrhoea still occurs in the well-informed and prepared traveller (<LINK REF="REF-McIntosh-1997" TYPE="REFERENCE">McIntosh 1997</LINK>), including those who stay exclusively in "five star" accommodation.</P>
<P>As the international traveller is often on a restricted schedule because of pre-planned tour itineraries or business demands, even a day lost to illness can be unexpectedly disruptive, creating a demand for prompt relief. Medical treatment may not always be easily accessible to the traveller because of factors such as an unfamiliar health system, language barriers, remoteness, and time constraints, so it is an attractive option for the traveller to carry self-treatment for some common conditions.</P>
<P>The mainstay of treatment for diarrhoea of all degrees of severity is adequate replacement of fluids and electrolytes. Moreover, the use of antibiotics to treat diarrhoea has been tested in a number of clinical trials (<LINK REF="REF-Katelaris-1995" TYPE="REFERENCE">Katelaris 1995</LINK>, <LINK REF="REF-NIH_x002d_CDCS-1985" TYPE="REFERENCE">NIH-CDCS 1985</LINK>).</P>
<P>This review was designed to examine the effectiveness of antibiotic treatment for acute diarrhoea. We also considered adverse effects reported in trials, as the aim of treatment is termination of diarrhoea and relief of symptoms, rather than reduction in a more serious clinical endpoint. We did not examine several other important issues, such as cost of treatment, which may be better evaluated in other ways.</P>
<P>Several related reviews are planned, including assessment of the effectiveness of non-antibiotic treatments, and of combination treatments for diarrhoea.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of antibiotics on diarrhoea in relation to: (a) duration of illness; (b) severity of illness; and (c) adverse effects.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-04 07:45:02 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-08-11 12:05:52 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All trials in any language in which travellers are randomly allocated to a treatment for non-bloody diarrhoea lasting not more than 14 days and where the causative organism is not known at allocation; to include placebo controlled trials and comparison trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults and children 5 years or older who develop acute non-bloody diarrhoea lasting not more than 14 days (i.e. to exclude dysentery and persistent diarrhoea at randomisation).</P>
<P>Travellers are defined as people who are travelling outside their usual country of residence, and are resident in the country of study for less than six months.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-08-11 11:59:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Any antibiotic therapy versus placebo.<BR/>2. Any antibiotic versus another antibiotic.</P>
<P>Treatments were self-administered or issued by a physician according to a study protocol with no prior knowledge of bacterial culture results.</P>
<P>Other treatments were acceptable within intervention and control groups, so long as both groups remain comparable in this respect; examples include fluid replacement, dietary advice, and malaria prophylaxis.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-11 12:05:52 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Duration</HEADING>
<P>Duration of diarrhoea, as assessed by time to last unformed stool.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Severity</HEADING>
<P>Number of loose stools passed per 24 hour period: 0-24 hours; 25-48 hours; 49-72 hours; &gt; 72 hours.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tolerability</HEADING>
<P>Number of subjects who report any side effect of treatment.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-04 07:44:15 +0100" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press or in progress).</P>
<P>The topic search terms used for searching trial registers and databases were: "travel$" for traveler, traveller, "diarr$" for "diarrhea", "diarrhoea", "diarrea", "reisediarrhoe", and "turista".</P>
<P>The Cochrane Infectious Diseases Group (CIDG) Specialized Register was searched for relevant trials up to September 2003. Details of the CIDG methods and the journals hand-searched are published in The Cochrane Library in the section on Collaborative Review Groups.</P>
<P>The Cochrane Central Register of Controlled Trials (CENTRAL) published in <I>The Cochrane Library </I>(Issue 3, 2004) was searched.</P>
<P>The following databases were searched using the topic search terms using the topic search terms in combination with the Cochrane highly sensitive search strategy for identifying trials as outlined in Appendix 5c of the Cochrane Handbook: MEDLINE (1966 to September 2003); and EMBASE (1988 to September 2003).</P>
<P>Additional trials were identified through hand searching of abstracts from the biennial International Society for Travel Medicine Conferences and other selected meetings including the annual meetings of the American Gastroenterological Society.</P>
<P>We contacted content experts in the field who have conducted and published randomised controlled trials on travellers' diarrhoea, aiming to identify any remaining published or unpublished trials. We also attempted to get original data from North American trialists, but these data could not be retrieved.<BR/>
<BR/>Finally, the reference lists in all identified studies were scanned in an effort to identify missing trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-04 07:45:02 +0100" MODIFIED_BY="[Empty name]">
<P>A full text version of each article identified through the various search strategies was independently assessed by two reviewers in terms of its quality in the following categories (for details see the Policy Statement of the Cochrane Infectious Diseases Group): allocation concealment; generation of allocation sequence; inclusion of all randomised participants.</P>
<P>Data extraction was performed for outcome variables.</P>
<P>Calculation of treatment effects was performed using Cochrane statistical software, RevMan version 4.04. Results of dichotomous variables are expressed as Mantel Haenszel odds ratio (OR) and 95% confidence interval (95% CI). Continuous outcomes are expressed as mean difference (MD) and 95% CI.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-11 12:29:48 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-08-11 12:10:52 +0100" MODIFIED_BY="[Empty name]">
<P>Thirty-three potentially eligible trials of antibiotic treatment for diarrhoea were identified. Twenty five studies were identified by searching MEDLINE, 11 by searching EMBASE (two unique), and four by hand searching of abstracts. An additional two unpublished articles were found through consultation with a content expert.</P>
<P>Six studies are awaiting further evaluation (See '<LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>'). This includes three trials published in German language journals. Two studies are unpublished trials about which the principal investigator provided methodological details, but requested that the data not be included. One trial was available only in abstract form, and further data are awaited. Two studies were excluded for not meeting inclusion criteria and three trials did not meet predefined quality assessments (see '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'). Of the remaining studies, two were duplicate publications of prior reports, and were considered together with the original study. This left a total of 20 studies which were included in the present analysis (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>').</P>
<P>Seven trials (<LINK REF="STD-Christensen-1988" TYPE="STUDY">Christensen 1988</LINK>, <LINK REF="STD-DuPont-1992" TYPE="STUDY">DuPont 1992</LINK>, <LINK REF="STD-Ericsson-1983" TYPE="STUDY">Ericsson 1983</LINK>, <LINK REF="STD-Mattila-1993" TYPE="STUDY">Mattila 1993</LINK>, <LINK REF="STD-Salam-1994" TYPE="STUDY">Salam 1994</LINK>, <LINK REF="STD-Wistrom-1989" TYPE="STUDY">Wistrom 1989</LINK>, <LINK REF="STD-Wistrom-1992" TYPE="STUDY">Wistrom 1992</LINK>) were studies of a single antibiotic agent against a placebo agent. Five trials (<LINK REF="STD-DuPont-1982" TYPE="STUDY">DuPont 1982</LINK>, <LINK REF="STD-DuPont-1992b" TYPE="STUDY">DuPont 1992b</LINK>, <LINK REF="STD-Ericsson-1987" TYPE="STUDY">Ericsson 1987</LINK>, <LINK REF="STD-Ericsson-1990" TYPE="STUDY">Ericsson 1990</LINK>, <LINK REF="STD-Steffen-1993" TYPE="STUDY">Steffen 1993</LINK>) were comparisons of multiple agents, or multiple regimens of a single agent, and included a placebo group. Five studies (<LINK REF="STD-DuPont-1984" TYPE="STUDY">DuPont 1984</LINK>, <LINK REF="STD-Ericsson-1992" TYPE="STUDY">Ericsson 1992</LINK>, <LINK REF="STD-Ericsson-1997" TYPE="STUDY">Ericsson 1997</LINK>, <LINK REF="STD-Kuschner-1995" TYPE="STUDY">Kuschner 1995</LINK>, <LINK REF="STD-Thornton-1992" TYPE="STUDY">Thornton 1992</LINK>) were direct comparisons of one antibiotic against another antibiotic, or multiple regimens of different durations using the same antibiotic, without use of a placebo group. Three studies (<LINK REF="STD-Ericsson-1986" TYPE="STUDY">Ericsson 1986</LINK>, <LINK REF="STD-Petrucelli-1992" TYPE="STUDY">Petrucelli 1992</LINK>, <LINK REF="STD-Taylor-1991" TYPE="STUDY">Taylor 1991</LINK>) compared an antibiotic against an antibiotic-antimotility agent combination.</P>
<P>Eleven studies were conducted in Mexico, of which 10 were among US adult students attending summer classes in Guadalajara, Mexico. Two studies were based in Thailand, and one each in Belize, Egypt, The Gambia, India, and Morocco. Two studies included people travelling to various destinations in developing nations.</P>
<P>The travellers in these studies were students (10 studies), military personnel (5 studies), "package" tourists (2 studies), resort guests (1 study), independent travellers (1 study), or volunteers recruited for the purpose of the study (1 study).</P>
<P>Inclusion criteria were fairly uniform across the studies, with all of the studies but three (<LINK REF="STD-Christensen-1988" TYPE="STUDY">Christensen 1988</LINK>, <LINK REF="STD-Salam-1994" TYPE="STUDY">Salam 1994</LINK>, <LINK REF="STD-Steffen-1993" TYPE="STUDY">Steffen 1993</LINK>) requiring participants to have a minimum of three loose stools per 24 hours before presentation or a smaller number of stools in a shorter period, such as two stools in 8 hours, and have evidence of an enteric illness, such as abdominal cramps, nausea, vomiting, and low grade fever. Inclusion criteria were not explicitly stated in one study (<LINK REF="STD-Christensen-1988" TYPE="STUDY">Christensen 1988</LINK>), and a single loose stool was sufficient for inclusion in two studies (<LINK REF="STD-Salam-1994" TYPE="STUDY">Salam 1994</LINK>, <LINK REF="STD-Steffen-1993" TYPE="STUDY">Steffen 1993</LINK>).</P>
<P>The agents evaluated in these trials included an oral flouroquinolone (ciprofloxacin, norfloxacin, or ofloxacin) in 12 studies (<LINK REF="STD-DuPont-1992b" TYPE="STUDY">DuPont 1992b</LINK>, <LINK REF="STD-Ericsson-1987" TYPE="STUDY">Ericsson 1987</LINK>, <LINK REF="STD-Ericsson-1997" TYPE="STUDY">Ericsson 1997</LINK>, <LINK REF="STD-Kuschner-1995" TYPE="STUDY">Kuschner 1995</LINK>, <LINK REF="STD-Mattila-1993" TYPE="STUDY">Mattila 1993</LINK>, <LINK REF="STD-Petrucelli-1992" TYPE="STUDY">Petrucelli 1992</LINK>, <LINK REF="STD-Salam-1994" TYPE="STUDY">Salam 1994</LINK>, <LINK REF="STD-Steffen-1993" TYPE="STUDY">Steffen 1993</LINK>, <LINK REF="STD-Wistrom-1989" TYPE="STUDY">Wistrom 1989</LINK>, <LINK REF="STD-Wistrom-1992" TYPE="STUDY">Wistrom 1992</LINK>), trimethoprim/ sulfamethoxazole in six studies (<LINK REF="STD-DuPont-1982" TYPE="STUDY">DuPont 1982</LINK>, <LINK REF="STD-Ericsson-1986" TYPE="STUDY">Ericsson 1986</LINK>, <LINK REF="STD-Ericsson-1987" TYPE="STUDY">Ericsson 1987</LINK>, <LINK REF="STD-Ericsson-1990" TYPE="STUDY">Ericsson 1990</LINK>, <LINK REF="STD-Ericsson-1992" TYPE="STUDY">Ericsson 1992</LINK>, <LINK REF="STD-Thornton-1992" TYPE="STUDY">Thornton 1992</LINK>), and in one study each for the following agents: ampicillin (<LINK REF="STD-DuPont-1984" TYPE="STUDY">DuPont 1984</LINK>), azithromycin (<LINK REF="STD-Kuschner-1995" TYPE="STUDY">Kuschner 1995</LINK>), aztreonam (<LINK REF="STD-DuPont-1992" TYPE="STUDY">DuPont 1992</LINK>), bicozamycin (<LINK REF="STD-Ericsson-1983" TYPE="STUDY">Ericsson 1983</LINK>), furazolidone (<LINK REF="STD-DuPont-1984" TYPE="STUDY">DuPont 1984</LINK>), pivmecillinam (<LINK REF="STD-Christensen-1988" TYPE="STUDY">Christensen 1988</LINK>), and trimethoprim alone (<LINK REF="STD-DuPont-1982" TYPE="STUDY">DuPont 1982</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-08-11 12:00:11 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Allocation</HEADING>
<P>All of the studies were randomised studies. Only one study reported on the method of randomisation used (<LINK REF="STD-DuPont-1982" TYPE="STUDY">DuPont 1982</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Eighteen studies were double-blinded, with one being single blinded (<LINK REF="STD-Ericsson-1997" TYPE="STUDY">Ericsson 1997</LINK>), and one study (<LINK REF="STD-Christensen-1988" TYPE="STUDY">Christensen 1988</LINK>) not reporting whether blinding was used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Inclusion of all randomised patients</HEADING>
<P>Included trials had losses to follow up or excluded patients from efficacy analysis that were less than 10% of randomised participants in all cases. Few studies reported an intention to treat analysis (<LINK REF="STD-Ericsson-1990" TYPE="STUDY">Ericsson 1990</LINK>, <LINK REF="STD-Ericsson-1992" TYPE="STUDY">Ericsson 1992</LINK>, <LINK REF="STD-Ericsson-1997" TYPE="STUDY">Ericsson 1997</LINK>).</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-11 12:29:48 +0100" MODIFIED_BY="[Empty name]">
<P>Data from studies comparing antibiotic treatment with placebo are presented in the summary analysis and in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. A total of 1474 patients were included in placebo-controlled studies.</P>
<P>A meta-analysis of the primary outcome, duration of diarrhoea after initiation of antibiotic treatment, or time to last unformed stool, was not performed. Of 12 placebo-controlled studies identified, 10 studies (<LINK REF="STD-DuPont-1982" TYPE="STUDY">DuPont 1982</LINK>, <LINK REF="STD-DuPont-1992" TYPE="STUDY">DuPont 1992</LINK>, <LINK REF="STD-DuPont-1992b" TYPE="STUDY">DuPont 1992b</LINK>, <LINK REF="STD-Ericsson-1983" TYPE="STUDY">Ericsson 1983</LINK>, <LINK REF="STD-Ericsson-1987" TYPE="STUDY">Ericsson 1987</LINK>, <LINK REF="STD-Ericsson-1990" TYPE="STUDY">Ericsson 1990</LINK>, <LINK REF="STD-Mattila-1993" TYPE="STUDY">Mattila 1993</LINK>, <LINK REF="STD-Salam-1994" TYPE="STUDY">Salam 1994</LINK>, <LINK REF="STD-Steffen-1993" TYPE="STUDY">Steffen 1993</LINK>, <LINK REF="STD-Wistrom-1989" TYPE="STUDY">Wistrom 1989</LINK>) reported data for this outcome. However, only three of these (<LINK REF="STD-DuPont-1992b" TYPE="STUDY">DuPont 1992b</LINK>, <LINK REF="STD-Ericsson-1983" TYPE="STUDY">Ericsson 1983</LINK>, <LINK REF="STD-Salam-1994" TYPE="STUDY">Salam 1994</LINK>) reported mean and standard deviation (SD) time to last unformed stool. One other study reported mean and a P value for a statistical test from which an imputed pooled SD could be derived (<LINK REF="STD-Wistrom-1992" TYPE="STUDY">Wistrom 1992</LINK>). The remaining six studies reported statistical comparisons that used non-parametric tests. In five cases, trials used the Wilcoxon test and one used the Mann-Whitney test.</P>
<P>In all 10 trials, a statistically significant reduction in time to last unformed stool was reported for participants receiving antibiotic treatment when compared with placebo, with the exception of the five day ofloxacin arm in <LINK REF="STD-DuPont-1992b" TYPE="STUDY">DuPont 1992b</LINK>. The data from the trials from which mean and SD could be obtained or imputed are presented in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>For the secondary efficacy endpoint of number of patients cured by 72 hours after randomisation, data from six trials (<LINK REF="STD-DuPont-1982" TYPE="STUDY">DuPont 1982</LINK>, <LINK REF="STD-Ericsson-1983" TYPE="STUDY">Ericsson 1983</LINK>, <LINK REF="STD-Mattila-1993" TYPE="STUDY">Mattila 1993</LINK>, <LINK REF="STD-Salam-1994" TYPE="STUDY">Salam 1994</LINK>, <LINK REF="STD-Steffen-1993" TYPE="STUDY">Steffen 1993</LINK>, <LINK REF="STD-Wistrom-1989" TYPE="STUDY">Wistrom 1989</LINK>) were available. Treatment with antibiotics resulted in a greater number of participants being cured of diarrhoea by 72 hours (OR 5.90, 95% CI 4.06 to 8.57, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>For the secondary endpoint of change in severity (number of unformed stools per 24 hour time interval), two trials (<LINK REF="STD-Ericsson-1983" TYPE="STUDY">Ericsson 1983</LINK>,<LINK REF="STD-Salam-1994" TYPE="STUDY">Salam 1994</LINK>) demonstrated a small reduction for antibiotic treated patients in the number of unformed stools passed per each 24 hour period from randomisation up to 72 hours (see <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). For the first 24 hours after randomisation, the difference was -1.59 stools (95% CI -2.66 to 0.52). For the period 25-48 hours, the difference was -2.10 stools (95% CI -2.78 to -1.42). For the third post-randomisation day, the difference was -1.38 stools (95% CI -1.94 to -0.82).</P>
<P>For the secondary endpoint of prevalence of any reported side effect of treatment, data from five trials (<LINK REF="STD-DuPont-1982" TYPE="STUDY">DuPont 1982</LINK>, <LINK REF="STD-DuPont-1992" TYPE="STUDY">DuPont 1992</LINK>, <LINK REF="STD-DuPont-1992b" TYPE="STUDY">DuPont 1992b</LINK>, <LINK REF="STD-Ericsson-1983" TYPE="STUDY">Ericsson 1983</LINK>, <LINK REF="STD-Steffen-1993" TYPE="STUDY">Steffen 1993</LINK>) were available. There were more side effects reported by persons taking antibiotics than those taking placebo (OR 2.37, 95% CI 1.50 to 3.75, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). There was significant variation in the incidence of side effects reported in different trials. Elimination of trials with the largest weight did not affect the overall result. Side effects reported were all noted to be not clinically serious, or resolved on withdrawal of the drug. Studies did not report examination for Clostridium difficile exotoxin in participants with recurrent diarrhoea. No studies reported fatalities or participants needing to be hospitalised after randomisation.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-04 08:07:45 +0100" MODIFIED_BY="[Empty name]">
<P>We examined the use of oral antibiotics for acute episodes of diarrhoea in travellers. The principal finding of this review was that a meta-analysis of the primary outcome was not feasible. The pooled results of the secondary endpoints demonstrate a significant beneficial effect of antibiotic treatment in terms of the proportion of persons taking antibiotics who were cured of diarrhoea by 72 hours of treatment, and in reducing the severity of illness. There were significantly more adverse effects reported in those taking antibiotics than those taking placebo. However, most of these side effects were minor, and resolved either spontaneously or on stopping the antibiotic.<BR/>The planned analyses of data for comparative trials of antibiotics and combination treatment were not carried out, principally because of concerns that the skewed nature of published data would imply a revision of the review methods.</P>
<P>Ten eligible trials reported summary measures based on mean, but only three reported both mean and SD. The ratios of mean and SD in these three trials also suggested that data for the primary outcome might be skewed; mean &lt; 1.6 SD. In one trial, a pooled SD could be calculated. The other six trials used non-parametric tests to compare the means from treatment and control groups. From this we infer that this was also because the data were not normally distributed, yet it was not stated clearly in any trials. For these reasons meta-analysis for the primary outcome data was not feasible.</P>
<P>One major problem with the analyses presented in these trials was that the primary outcome was not treated as a time-to-event outcome. The proper analysis of such data would require time to event analysis, such as Kaplan-Meier life table methods, comparing groups using the log rank test. If such an analysis can be undertaken, it would strengthen the reliability of the conclusions.</P>
<P>The trials examined in this systematic review used similar entry criteria, with three exceptions (<LINK REF="STD-Christensen-1988" TYPE="STUDY">Christensen 1988</LINK>, <LINK REF="STD-Salam-1994" TYPE="STUDY">Salam 1994</LINK>, <LINK REF="STD-Steffen-1993" TYPE="STUDY">Steffen 1993</LINK>). Participants could be regarded as having had "classic travellers' diarrhoea" (<LINK REF="REF-Steffen-1999" TYPE="REFERENCE">Steffen 1999</LINK>), or moderate to severe diarrhoeal illness to have been included in these studies. Part of the reason for this uniformity is that many of the studies were performed in the same geographic location, using similar protocols, in consistent participant populations.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Available trial data demonstrate that antibiotic treatment is effective in reducing the duration of post-treatment diarrhoea, and severity of diarrhoea. However, this is at the price of an increased chance of side effects from antibiotic treatment.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The quality of information included in reports of therapeutic trials must meet certain minimum criteria. It is no longer accepted practice for authors to omit confidence interval data or measures of variation of the mean from reports of statistical testing. It is also crucial that data be appropriately analysed. The primary outcome for this review is ideally represented in a time-to-event analysis. Thorough statistical review of papers before publication should prevent such errors.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Dr Paul Garner for general guidance, and Dr Paula Williamson for statistical advice. Dr HL DuPont provided access to unpublished trials, which are awaiting further analysis.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>We certify that we have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of the review (e.g. employment, consultancy, stock ownership, honoraria, expert testimony).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-10-04 07:47:07 +0100" MODIFIED_BY="[Empty name]">
<P>Not stated.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2012-01-17 10:51:49 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>2012, Issue 2: Review status: Current question - update pending. New studies have been identified; a new author team is required for this review.</P>
<P>The Cochrane Infectious Diseases Group assesses Review Status using a pilot system to help the reader understand whether the review concerns a current question, and is up to date. We report on:</P>
<P>1. The question the review addresses. Is it a:</P>
<UL>
<LI>
<B>Historical question</B>, where the intervention or policy has been superseded by new medical developments (such as a new drug); or a</LI>
<LI>
<B>Current question</B>, which is still relevant to current policy or practice.</LI>
</UL>
<P>
<B>2. </B>Whether the review is up to date. Is the review:</P>
<UL>
<LI>
<B>Up to date</B>;</LI>
<LI>
<B>Update pending</B>; or</LI>
<LI>
<B>No update intended</B>.</LI>
</UL>
<P>We then provide comment of the review status, to help explain the categories selected.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-04 08:31:26 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-10-04 08:31:06 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Christensen-1988" NAME="Christensen 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Christensen OE, Tuxen KK, Menday P. Treatment of travellers' diarrhoea with pivmecillinam [letter]. J Antimicrob Chemother 1988; 22:  570-1.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christensen OE, Tuxen KK, Menday P</AU>
<TI>Treatment of travellers' diarrhoea with pivmecillinam [letter]</TI>
<SO>J Antimicrob Chemother</SO>
<YR>1988</YR>
<VL>22</VL>
<PG>570-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DuPont-1982" NAME="DuPont 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;DuPont HL, Ericsson CD, Reves RR, Galindo E. Antimicrobial therapy for travelers' diarrhea. Rev Infect Dis 1986; 8 (Suppl 2): S217-22.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DuPont HL, Ericsson CD, Reves RR, Galindo E</AU>
<TI>Antimicrobial therapy for travelers' diarrhea</TI>
<SO>Rev Infect Dis</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>Suppl 2</NO>
<PG>S217-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;DuPont HL, Reves RR, Galindo E, Sullivan PS, Wood LV, Mendiola JG. Treatment of travelers' diarrhea with trimethoprim / sulfamethoxazole and with trimethoprim alone. N Engl J Med 1982; 307: 841-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DuPont HL, Reves RR, Galindo E, Sullivan PS, Wood LV, Mendiola JG</AU>
<TI>Treatment of travelers' diarrhea with trimethoprim / sulfamethoxazole and with trimethoprim alone</TI>
<SO>N Engl J Med</SO>
<YR>1982</YR>
<VL>307</VL>
<PG>841-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Dupont HL, Ericsson CD, Galindo E, Dupont MW, Mendiola Gomez J. Antimicrobial therapy of travellers' diarrhoea. Scand J Gastroenterol Suppl 1983; 84: 99-105.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dupont HL, Ericsson CD, Galindo E, Dupont MW, Mendiola Gomez J</AU>
<TI>Antimicrobial therapy of travellers' diarrhoea</TI>
<SO>Scand J Gastroenterol Suppl</SO>
<YR>1983</YR>
<VL>84</VL>
<PG>99-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DuPont-1984" NAME="DuPont 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;DuPont HL, Ericsson CD, Galindo E, Wood LV, Morgan D, Bitsura JA, Mendiola JG. Furazolidone versus ampicillin in the treatment of traveler's diarrhea. Antimicrob Agents Chemother 1984; 26: 160-3.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DuPont HL, Ericsson CD, Galindo E, Wood LV, Morgan D, Bitsura JA, Mendiola JG</AU>
<TI>Furazolidone versus ampicillin in the treatment of traveler's diarrhea</TI>
<SO>Antimicrob Agents Chemother</SO>
<YR>1984</YR>
<VL>26</VL>
<PG>160-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;DuPont HL, Ericsson CD, Reves RR, Galindo E. Antimicrobial therapy for travelers' diarrhea. Rev Infect Dis 1986; 8 (Suppl 2): S217-22.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DuPont HL, Ericsson CD, Reves RR, Galindo E</AU>
<TI>Antimicrobial therapy for travelers' diarrhea</TI>
<SO>Rev Infect Dis</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>Suppl 2</NO>
<PG>S217-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DuPont-1992" NAME="DuPont 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;DuPont HL, Ericsson CD, Mathewson JJ, De la Cabada FJ, Conrad DA.  Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico.  JAMA 1992; 267: 1932 - 1935.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DuPont HL, Ericsson CD, Mathewson JJ, De la Cabada FJ, Conrad DA</AU>
<TI>Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico</TI>
<SO>JAMA</SO>
<YR>1992</YR>
<VL>267</VL>
<PG>1932 - 1935</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DuPont-1992b" NAME="DuPont 1992b" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;DuPont HL, Ericsson CS, Mathewson JJ, DuPont MW.  Five versus three days of ofloxacin therapy for traveler's diarrhea:  a placebo - controlled study.  Antimicrob Ag Chemo 1992; 36: 87 - 91.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DuPont HL, Ericsson CS, Mathewson JJ, DuPont MW</AU>
<TI>Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo - controlled study</TI>
<SO>Antimicrob Ag Chemo</SO>
<YR>1992</YR>
<VL>36</VL>
<PG>87 - 91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ericsson-1983" NAME="Ericsson 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;DuPont HL, Ericsson CD, Reves RR, Galindo E. Antimicrobial therapy for travelers' diarrhea. Rev Infect Dis 1986; 8 (Suppl 2): S217-22.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DuPont HL, Ericsson CD, Reves RR, Galindo E</AU>
<TI>Antimicrobial therapy for travelers' diarrhea</TI>
<SO>Rev Infect Dis</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>Suppl 2</NO>
<PG>S217-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Dupont HL, Ericsson CD, Galindo E, Dupont MW, Mendiola Gomez J. Antimicrobial therapy of travellers' diarrhoea. Scand J Gastroenterol Suppl 1983; 84: 99-105.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dupont HL, Ericsson CD, Galindo E, Dupont MW, Mendiola Gomez J</AU>
<TI>Antimicrobial therapy of travellers' diarrhoea</TI>
<SO>Scand J Gastroenterol Suppl</SO>
<YR>1983</YR>
<VL>84</VL>
<PG>99-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Ericsson CD, DuPont HL, Sullivan P, Galindo E, Evans DG, Evans DJ Jr. Bicozamycin, a poorly absorbable antibiotic, effectively treats travelers' diarrhea. Ann Intern Med 1983; 98: 20-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ericsson CD, DuPont HL, Sullivan P, Galindo E, Evans DG, Evans DJ Jr</AU>
<TI>Bicozamycin, a poorly absorbable antibiotic, effectively treats travelers' diarrhea</TI>
<SO>Ann Intern Med</SO>
<YR>1983</YR>
<VL>98</VL>
<PG>20-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ericsson-1986" NAME="Ericsson 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Ericsson CD, Johnson PC, DuPont HL, Morgan DR. Role of a novel antidiarrheal agent, BW942C, alone or in combination with trimethoprim-sulfamethoxazole in the treatment of traveler's diarrhea. Antimicrob Agents Chemother 1986; 29: 1040-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ericsson CD, Johnson PC, DuPont HL, Morgan DR</AU>
<TI>Role of a novel antidiarrheal agent, BW942C, alone or in combination with trimethoprim-sulfamethoxazole in the treatment of traveler's diarrhea</TI>
<SO>Antimicrob Agents Chemother</SO>
<YR>1986</YR>
<VL>29</VL>
<PG>1040-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ericsson-1987" NAME="Ericsson 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Ericsson CD, Johnson PC, Dupont HL, Morgan DR, Bitsura JA, de la Cabada FJ. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea, A placebo-controlled, randomized trial. Ann Intern Med 1987; 106: 216-20.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ericsson CD, Johnson PC, Dupont HL, Morgan DR, Bitsura JA, de la Cabada FJ</AU>
<TI>Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea, A placebo-controlled, randomized trial</TI>
<SO>Ann Intern Med</SO>
<YR>1987</YR>
<VL>106</VL>
<PG>216-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ericsson-1990" NAME="Ericsson 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Ericsson CD, DuPont HL, Mathewson JJ, West MS, Johnson PC,  Bitsura JA. Treatment of traveler's diarrhea with sulfamethoxazole and trimethoprim and loperamide. JAMA 1990; 263: 257-61.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ericsson CD, DuPont HL, Mathewson JJ, West MS, Johnson PC, Bitsura JA</AU>
<TI>Treatment of traveler's diarrhea with sulfamethoxazole and trimethoprim and loperamide</TI>
<SO>JAMA</SO>
<YR>1990</YR>
<VL>263</VL>
<PG>257-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ericsson-1992" NAME="Ericsson 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Ericsson CD, Nicholls-Vasquez I, DuPont HL, Mathewson JJ. Optimal dosing of trimethoprim-sulfamethoxazole when used with loperamide to treat traveler's diarrhea. Antimicrob Agents Chemother 1992; 36: 2821 - 4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ericsson CD, Nicholls-Vasquez I, DuPont HL, Mathewson JJ</AU>
<TI>Optimal dosing of trimethoprim-sulfamethoxazole when used with loperamide to treat traveler's diarrhea</TI>
<SO>Antimicrob Agents Chemother</SO>
<YR>1992</YR>
<VL>36</VL>
<PG>2821 - 4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ericsson-1997" NAME="Ericsson 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Ericsson CD, DuPont HL, Mathewson JJ.  Single dose ofloxacin plus loperamide compared with single dose or three days of ofloxacin in the treatment of traveler's diarrhea.  J Travel Med 1997; 4: 3 - 7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ericsson CD, DuPont HL, Mathewson JJ</AU>
<TI>Single dose ofloxacin plus loperamide compared with single dose or three days of ofloxacin in the treatment of traveler's diarrhea</TI>
<SO>J Travel Med</SO>
<YR>1997</YR>
<VL>4</VL>
<PG>3 - 7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuschner-1995" NAME="Kuschner 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Kuschner RA, Trofa AF,  Thomas RJ, et al.  Use of azithromycin for the treatment of campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent.  Clin Infect Dis 1995; 21: 536 - 41.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuschner RA, Trofa AF, Thomas RJ, et al</AU>
<TI>Use of azithromycin for the treatment of campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent</TI>
<SO>Clin Infect Dis</SO>
<YR>1995</YR>
<VL>21</VL>
<PG>536 - 41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattila-1993" NAME="Mattila 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Mattila L, Peltola H, Siitonen A, Kyronseppa H, Simula I, Kataja M.  Short term treatment of traveler's diarrhea with norfloxacin:  a double-blind, placebo-controlled study during two seasons.  Clin Infect Dis 1993; 17: 779 - 82.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattila L, Peltola H, Siitonen A, Kyronseppa H, Simula I, Kataja M</AU>
<TI>Short term treatment of traveler's diarrhea with norfloxacin: a double-blind, placebo-controlled study during two seasons</TI>
<SO>Clin Infect Dis</SO>
<YR>1993</YR>
<VL>17</VL>
<PG>779 - 82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrucelli-1992" NAME="Petrucelli 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Petruccelli BP, Murphy GS, Sanchez JL  et al. Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J Infect Dis 1992; 165: 557-60&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petruccelli BP, Murphy GS, Sanchez JL et al</AU>
<TI>Treatment of traveler's diarrhea with ciprofloxacin and loperamide</TI>
<SO>J Infect Dis</SO>
<YR>1992</YR>
<VL>165</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salam-1994" NAME="Salam 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Salam I, Katelaris P, Leigh-Smith S, Farthing MJ. Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea. Lancet 1994; 344: 1537-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salam I, Katelaris P, Leigh-Smith S, Farthing MJ</AU>
<TI>Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>344</VL>
<PG>1537-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steffen-1993" NAME="Steffen 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Steffen R, Jori R, DuPont HL, Mathewson JJ, Sturchler D.  Efficacy and toxicity of fleroxacin in the treatment of traveler's diarrhea.  Am J Med 1993; Vol 94 (suppl 3A): S182 - 186.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steffen R, Jori R, DuPont HL, Mathewson JJ, Sturchler D</AU>
<TI>Efficacy and toxicity of fleroxacin in the treatment of traveler's diarrhea</TI>
<SO>Am J Med</SO>
<YR>1993</YR>
<VL>Vol 94</VL>
<NO>suppl 3A</NO>
<PG>S182 - 186</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Steffen R, Jori R, DuPont HL, Mathewson JJ, Sturchler D.  Treatment of travellers' diarrhoea with fleroxacin: a case study.  J Antimicrob Chemo 1993; 31: 767 - 776.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steffen R, Jori R, DuPont HL, Mathewson JJ, Sturchler D</AU>
<TI>Treatment of travellers' diarrhoea with fleroxacin: a case study</TI>
<SO>J Antimicrob Chemo</SO>
<YR>1993</YR>
<VL>31</VL>
<PG>767 - 776</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-1991" NAME="Taylor 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Taylor DN, Sanchez JL, Candler W, Thornton S, McQueen C, Echeverria P. Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann Intern Med 1991; 114: 731-4.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor DN, Sanchez JL, Candler W, Thornton S, McQueen C, Echeverria P</AU>
<TI>Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial</TI>
<SO>Ann Intern Med</SO>
<YR>1991</YR>
<VL>114</VL>
<PG>731-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thornton-1992" NAME="Thornton 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Thornton SA, Wignall SF, Kilpatrick ME, Bourgeois AL, Gardiner C, Batchelor RA, Burr DH, Oprandy JJ, Garst P, Hyams KC. Norfloxacin compared to trimethoprim / sulfamethoxazole for the treatment of travelers' diarrhea among U.S. military personnel deployed to South America and West Africa. Mil Med 1992; 157: 55-8.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thornton SA, Wignall SF, Kilpatrick ME, Bourgeois AL, Gardiner C, Batchelor RA, Burr DH, Oprandy JJ, Garst P, Hyams KC</AU>
<TI>Norfloxacin compared to trimethoprim / sulfamethoxazole for the treatment of travelers' diarrhea among U.S. military personnel deployed to South America and West Africa</TI>
<SO>Mil Med</SO>
<YR>1992</YR>
<VL>157</VL>
<PG>55-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wistrom-1989" NAME="Wistrom 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Wistrom J, Jertborn M, Hedstrom SA,  Alestig K,  Englund G,  Jellheden B, Norrby SR. Short-term self-treatment of travellers' diarrhoea with norfloxacin: a placebo-controlled study. J Antimicrob Chemother 1989; 23: 905 - 13.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wistrom J, Jertborn M, Hedstrom SA, Alestig K, Englund G, Jellheden B, Norrby SR</AU>
<TI>Short-term self-treatment of travellers' diarrhoea with norfloxacin: a placebo-controlled study</TI>
<SO>J Antimicrob Chemother</SO>
<YR>1989</YR>
<VL>23</VL>
<PG>905 - 13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wistrom-1992" NAME="Wistrom 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Wistrom J, Gentry LO, Palmgren AC, Price M, Nord CE, Ljungh A, Norrby SR. Ecological effects of short-term ciprofloxacin treatment of travellers' diarrhoea. J Antimicrob Chemother 1992; 30: 693-706.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wistrom J, Gentry LO, Palmgren AC, Price M, Nord CE, Ljungh A, Norrby SR</AU>
<TI>Ecological effects of short-term ciprofloxacin treatment of travellers' diarrhoea</TI>
<SO>J Antimicrob Chemother</SO>
<YR>1992</YR>
<VL>30</VL>
<PG>693-706</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-10-04 08:11:29 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bouree-1987" NAME="Bouree 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Bouree P, Kouchner G, Ponti M. Double-blind study of traveller's diarrhoea using Nifuroxazide. Trans R Soc Trop Med Hyg 1987; 81: 859.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bouree P, Kouchner G, Ponti M</AU>
<TI>Double-blind study of traveller's diarrhoea using Nifuroxazide</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1987</YR>
<VL>81</VL>
<PG>859</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chagnon-1996" MODIFIED="2008-10-04 08:11:29 +0100" MODIFIED_BY="[Empty name]" NAME="Chagnon 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-04 08:11:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Chagnon-A [Travelers' diarrhea]. Rev-Prat 1996; 46: 189-95.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-04 08:11:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chagnon A</AU>
<TI>Travelers' diarrhea</TI>
<SO>Revue du Praticien</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>2</NO>
<PG>189-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hill-1961" NAME="Hill 1961" YEAR="1961">
<REFERENCE NOTES="&lt;p&gt;Hill JA. Diarrhoea in Aden - a therapeutic trial. Trans R Soc Trop Med Hyg 1961; 55: 355-360&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hill JA</AU>
<TI>Diarrhoea in Aden - a therapeutic trial</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1961</YR>
<VL>55</VL>
<PG>355-360</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richards-1970" NAME="Richards 1970" YEAR="1970">
<REFERENCE NOTES="&lt;p&gt;Richards DA.  A controlled trial in travelers' diarrhoea.  Practitioner 1970; 204: 822 - 824&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richards DA</AU>
<TI>A controlled trial in travelers' diarrhoea</TI>
<SO>Practitioner</SO>
<YR>1970</YR>
<VL>204</VL>
<PG>822 - 824</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steffen-1988" NAME="Steffen 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Steffen R, Heusser T, Schopp A, DuPont H. Efficacy and side-effects of six agents in the self-treatment of traveler's diarrhea.Travel Medicine International 1988; 6: 153-157.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steffen R, Heusser T, Schopp A, DuPont H</AU>
<TI>Efficacy and side-effects of six agents in the self-treatment of traveler's diarrhea</TI>
<SO>Travel Medicine International</SO>
<YR>1988</YR>
<VL>6</VL>
<PG>153-157</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-10-04 08:31:06 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1995" MODIFIED="2008-10-04 08:29:20 +0100" MODIFIED_BY="[Empty name]" NAME="Anonymous 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-10-04 08:29:20 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;AUTHORS. Ciprofloxacin-Einmaldosis zur Behandlung der Reisediarrhoe. Dtsch-Med-Wochenschr. [Single-dose ciprofloxacin in the treatment of traveller's diarrhoea] 1995;120(25-26): 943&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-04 08:29:20 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>No authors listed</AU>
<TI>Single-dose ciprofloxacin in the treatment of traveller's diarrhoea</TI>
<TO>Ciprofloxacin-einmaldosis zur behandlung der reisediarrhoe</TO>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1995</YR>
<VL>120</VL>
<NO>25-6</NO>
<PG>943</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruns-1995" MODIFIED="2008-10-04 08:13:17 +0100" MODIFIED_BY="[Empty name]" NAME="Bruns 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-10-04 08:13:17 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bruns R.  Raedsch R. THERAPIE DER REISEDIARRHOE. Medizinische Welt [Therapy of traveller's diarrhea] 1995.; 46(12):591-596&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-04 08:13:17 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruns R, Raedsch R</AU>
<TI>Therapy of traveller's diarrhea</TI>
<TO>Therapie der reisediarrhoe</TO>
<SO>Medizinische Welt</SO>
<YR>1995</YR>
<VL>46</VL>
<NO>12</NO>
<PG>591-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-DuPont-1994" NAME="DuPont 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Otsuka Pharmaceuticals, study no 106-92-212. &lt;br&gt;Double-blind,  active-controlled, efficacy study of grepafloxacin (OPC 17116) therapy  in the treatment of traveller's diarrhoea.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otsuka Pharmaceuticals, study no 106-92-212</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-DuPont-1994b" NAME="DuPont 1994b" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Otsuka Pharmaceuticals study no 106-92-209.&lt;br&gt;Evaluation of 4 dosage regimens of grepafloxacin in the treatment of bacterial (traveler's diarrhoea)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otsuka Pharmaceuticals study no 106-92-209</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DuPont-1997" MODIFIED="2008-10-04 08:25:21 +0100" MODIFIED_BY="[Empty name]" NAME="DuPont 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-10-04 08:25:21 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DuPont HL, Ericsson CD, Mathewson JJ, Palazzini E, DuPont MW, DeLa Cabada FJ. Rifaximin - a nonabsorbed antimicrobial in the therapy of travelers' diarrhea in Guadalajara, Mexico. The Fifth International Conference on Travel Medicine. March 1997. Geneva, Switzerland 1997, Abstract 208&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-04 08:25:21 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>DuPont HL, Ericsson CD, Mathewson JJ, Palazzini E, DuPont MW, DeLa Cabada FJ</AU>
<TI>Rifaximin - a nonabsorbed antimicrobial in the therapy of travelers' diarrhea in Guadalajara, Mexico</TI>
<SO>The Fifth International Conference on Travel Medicine</SO>
<YR>March 1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziegenhagen-1992" MODIFIED="2008-10-04 08:31:06 +0100" MODIFIED_BY="[Empty name]" NAME="Ziegenhagen 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-10-04 08:31:06 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ziegenhagen DJ.  Raedsch R.  Kruis W. Reisediarrho in der Turkei. Prospektiv randomisierter Therapievergleich Kohle versus Tanninalbuminat/Ethacridinlactat. Medizinische Klinik [Traveler's diarrhea in Turkey. Prospective randomized therapeutic comparison of charcoal versus tannin albuminate/ethacridine lactate. (German)] 1992;  87: 637-9.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-04 08:31:06 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ziegenhagen DJ, Raedsch R, Kruis W</AU>
<TI>Traveler's diarrhea in Turkey. Prospective randomized therapeutic comparison of charcoal versus tannin albuminate/ethacridine lactate</TI>
<TO>Reisediarrho in der Turkei. Prospektiv randomisierter therapievergleich kohle versus tanninalbuminat/ethacridinlactat</TO>
<SO>Medizinische Klinik</SO>
<YR>1992</YR>
<VL>87</VL>
<NO>12</NO>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-04 08:31:26 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-04 08:31:26 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Black-1986" NAME="Black 1986" TYPE="JOURNAL_ARTICLE">
<AU>Black RE</AU>
<TI>Pathogens that cause traveler's diarrhea in Latin America and Africa</TI>
<SO>Rev Infect Dis</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>Suppl 2</NO>
<PG>S131-S135</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BSSI-1996" NAME="BSSI 1996" TYPE="JOURNAL_ARTICLE">
<AU>Farthing M, Feldman R, Finch R Fox R, Leen C, Mandal B Moss P, Nathwani D, Nye F, Ritchie L, Todd W, Wood M</AU>
<TI>The management of infective gastroenteritis in adults. A consensus statement by an expert panel convened by the British Society for the Study of Infection</TI>
<SO>J Inf</SO>
<YR>1996</YR>
<VL>33</VL>
<PG>143-152</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cartwright-1997" MODIFIED="2008-08-11 14:41:43 +0100" MODIFIED_BY="[Empty name]" NAME="Cartwright 1997" TYPE="JOURNAL_ARTICLE">
<AU>Cartwright RY, Chahed M</AU>
<TI>Foodborne diseases in travellers</TI>
<SO>World Health Statistics Quarterly</SO>
<YR>1997</YR>
<VL>50</VL>
<PG>102-110</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DuPont-1993" NAME="DuPont 1993" TYPE="JOURNAL_ARTICLE">
<AU>DuPont HL, Ericsson CD</AU>
<TI>Prevention and treatment of traveler's diarrhea</TI>
<SO>N Engl J Med</SO>
<YR>1993</YR>
<VL>328</VL>
<PG>1821-1827</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farthing-1992" MODIFIED="2008-08-11 14:32:52 +0100" MODIFIED_BY="[Empty name]" NAME="Farthing 1992" TYPE="JOURNAL_ARTICLE">
<AU>Farthing M, et al</AU>
<TI>Treatment and prevention of traveller's diarrhoea</TI>
<SO>Gastroenterology International</SO>
<YR>1992</YR>
<VL>5</VL>
<PG>162-175</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gorbach-1975" NAME="Gorbach 1975" TYPE="JOURNAL_ARTICLE">
<AU>Gorbach SL, Kean BH, Evans DG, Evans D, Bessudo D</AU>
<TI>Traveler's diarrhea and toxigenic Escherichia coli</TI>
<SO>N Engl J Med</SO>
<YR>1975</YR>
<VL>292</VL>
<PG>933-936</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hundt-1996" MODIFIED="2008-10-04 08:31:26 +0100" MODIFIED_BY="[Empty name]" NAME="Hundt 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hundt A</AU>
<TI>Impact of tourism development on the economy and health of Third World Nations</TI>
<SO>J Travel Med</SO>
<YR>1996</YR>
<VL>3</VL>
<PG>107-112</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Katelaris-1995" MODIFIED="2008-08-11 14:33:03 +0100" MODIFIED_BY="[Empty name]" NAME="Katelaris 1995" TYPE="JOURNAL_ARTICLE">
<AU>Katelaris PH, Farthing MJ</AU>
<TI>Traveler's diarrhea: clinical presentation and prognosis</TI>
<SO>Chemotherapy</SO>
<YR>1995</YR>
<VL>41 Suppl 1</VL>
<PG>40-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McIntosh-1997" NAME="McIntosh 1997" TYPE="JOURNAL_ARTICLE">
<AU>McIntosh IB, Reed JM, Power KG</AU>
<TI>Traveller's diarrhoea and the effect of pre-travel health advice in general practice</TI>
<SO>Br J Gen Pract</SO>
<YR>1997</YR>
<VL>47</VL>
<PG>71-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIH_x002d_CDCS-1985" MODIFIED="2008-10-04 08:18:40 +0100" MODIFIED_BY="[Empty name]" NAME="NIH-CDCS 1985" TYPE="JOURNAL_ARTICLE">
<AU>[No authors listed]</AU>
<TI>Travelers' diarrhea. NIH Consensus Development Conference</TI>
<SO>JAMA</SO>
<YR>1985</YR>
<VL>253</VL>
<NO>18</NO>
<PG>2700-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steffen-1983" NAME="Steffen 1983" TYPE="JOURNAL_ARTICLE">
<AU>Steffen R, van der Linde F, Gyr K, Schar M</AU>
<TI>Epidemiology of Diarrhea in Travelers</TI>
<SO>JAMA</SO>
<YR>1983</YR>
<VL>249</VL>
<PG>1176-1180</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steffen-1999" MODIFIED="2008-08-11 14:21:51 +0100" MODIFIED_BY="[Empty name]" NAME="Steffen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Steffen R, Collard F, Tornieporth N, et al</AU>
<TI>Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>281</VL>
<PG>811-17</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-10-04 08:35:48 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-10-04 08:35:48 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-10-04 07:50:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christensen-1988">
<CHAR_METHODS MODIFIED="2008-10-04 07:50:00 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:50:03 +0100" MODIFIED_BY="[Empty name]">
<P>65 Danish tourists on a 2 week trip to India</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:50:04 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Pivmecillinam 400 mg orally three times daily for 3 days</P>
<P>Comparison: Matching placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:50:04 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of post-treatment diarrhoea</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 07:50:07 +0100" MODIFIED_BY="[Empty name]">
<P>Stool cultures were not obtained by investigators</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 07:55:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DuPont-1982">
<CHAR_METHODS MODIFIED="2008-10-04 07:55:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Patients sequentially allocated to one of three preparations, which had been randomly ordered using procedure PLAN of the Statistical Analysis System</P>
<P>Patients kept daily diary of symptoms and medication doses They were seen daily in the study clinic</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:50:12 +0100" MODIFIED_BY="[Empty name]">
<P>110 US students attending summer school in Guadalajara, Mexico during the summer of 1981</P>
<P>Entry criteria: four or more unformed stools per 24 hours or three unformed stools per 8 hours; diarrhoea of no more than 48 hours' duration; at least one of: abdominal pain, cramps, nausea, vomiting, or dysentery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:52:59 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment:<BR/>1. Trimethoprim/ sulfamethoxazole 160/800 mg twice daily for 5 days<BR/>2. Trimethoprim 200 mg twice daily for 5 days</P>
<P>Comparison:<BR/>3. Placebo twice daily for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:50:21 +0100" MODIFIED_BY="[Empty name]">
<P>1. Number of unformed stools passed<BR/>2. Number of hours to last unformed stool<BR/>3. Failure: Diarrhoea persisting longer than the 5 day treatment period or with clinical evidence of worsening illness while on treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 07:50:26 +0100" MODIFIED_BY="[Empty name]">
<P>83 participants (75%) had positive stool cultures</P>
<P>Major pathogenic organisms: ETEC - (58%), Shigella - 23 (21%), Salmonella - 5 (5%)</P>
<P>No pre- or post-treatment antibiotic sensitivities reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 07:50:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DuPont-1984">
<CHAR_METHODS MODIFIED="2008-10-04 07:50:40 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation not stated</P>
<P>Patients kept daily diary of symptoms and medication doses</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:50:45 +0100" MODIFIED_BY="[Empty name]">
<P>100 US students attending summer school in Guadalajara, Mexico</P>
<P>Entry criteria: four or more unformed stools pers 24 hours or three unformed stools per 8 hours; diarrhoea of no more than 60 hours' duration; at least one of: abdominal pain, cramps, nausea, vomiting, fever</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:50:47 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Furazolidone 100 mg orally four times daily for 5 days</P>
<P>Comparison: Ampicillin 500 mg orally four times daily for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:50:50 +0100" MODIFIED_BY="[Empty name]">
<P>Time from initiation of treatment to passage of last unformed stool</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 07:56:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DuPont-1992">
<CHAR_METHODS MODIFIED="2008-10-04 07:50:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation not stated</P>
<P>Patients kept daily diary of symptoms and medication doses</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:50:59 +0100" MODIFIED_BY="[Empty name]">
<P>191 US students attending summer school in Guadalajara, Mexico during the summers of 1989 and 1990</P>
<P>Entry criteria: four or more unformed stools pers 24 hours or three unformed stools per 8 hours; diarrhoea of no more than 72 hours' duration; at least one of: abdominal pain, cramps, nausea, vomiting, fever</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:51:01 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Aztreonam 100 mg three times a day for 5 days</P>
<P>Placebo: Matching placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:51:08 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical recovery: duration of post-treatment diarrhoea, proportion of each group with clinical recovery by time interval post initiation of treatment<BR/>2. Treatment failures<BR/>3. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 07:56:26 +0100" MODIFIED_BY="[Empty name]">
<P>81 participants (42%) had positive stool cultures</P>
<P>Major pathogenic organisms: ETEC - 61 (32%), Shigella - 7 (4%). Others: Aeromonas, Edwardsiella, Plesiomonas, Salmonella</P>
<P>100% of pretreatment stools sensitive to aztreonam and norfloxacin. Reduced sensitivity to TMP/SMX: ETEC 91%, Shigella 91%, Salmonella 60%</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 07:56:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DuPont-1992b">
<CHAR_METHODS MODIFIED="2008-10-04 07:56:32 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation not stated</P>
<P>Two patients were assigned ofloxacin for every patient assigned placebo</P>
<P>Patients kept daily diary of symptoms and medication doses</P>
<P>Patients were seen daily and questioned by investigators</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:56:34 +0100" MODIFIED_BY="[Empty name]">
<P>232 US students attending summer school in Guadalajara, Mexico during the period from June 1986 and December 1988</P>
<P>Entry criteria: four or more unformed stools pers 24 hours or three unformed stools per 8 hours; diarrhoea of no more than 60 hours' duration; other abdominal complaints, such as abdominal discomfort, urgency; or fever</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:56:37 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment groups:<BR/>1. Ofloxacin 300 mg orally twice daily for three days<BR/>2. Ofloxacin 300 mg orally twice daily for five days</P>
<P>Placebo groups:<BR/>3. Placebo orally twice daily for three days<BR/>4. Placebo orally twice daily for five days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:56:48 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical response<BR/>2. Cure: complete resolution of illness<BR/>3. Duration of post treatment diarrhoea<BR/>4. Failure: Deterioration of clinical status during treatment or diarrhoea persisting 5 days or longer after treatment was begun</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 07:56:54 +0100" MODIFIED_BY="[Empty name]">
<P>103 participants (44%) had 124 pathogens isolated</P>
<P>Major pathogenic organisms: ETEC - 66 (28%), Shigella - 24 (10%), Plesiomonas -14 (6%)</P>
<P>Others: Aeromonas, Campylobacter, ETEC, Salmonella</P>
<P>Pre- and post-treatment antibiotic sensitivities not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 07:57:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ericsson-1983">
<CHAR_METHODS MODIFIED="2008-10-04 07:56:59 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation not stated</P>
<P>Patients kept daily diary of symptoms and medication doses</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:57:03 +0100" MODIFIED_BY="[Empty name]">
<P>148 US students attending summer school in Guadalajara, Mexico during the summer of 1980</P>
<P>Entry criteria: four or more unformed stools pers 24 hours or three unformed stools per 8 hours; diarrhoea of no more than 48 hours' duration; at least one of: abdominal pain, cramps, nausea, vomiting, fever</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:57:04 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Bicozamycin 500 mg orally 4 times daily for 3 days</P>
<P>Comparison: Placebo orally 4 times daily for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:57:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Time from initiation of treatment to passage of last unformed stool<BR/>2. Number of unformed stools passed per 24 hour interval from initiation of treatment<BR/>3. Failed: Moderate to severe illness with more than 6 unformed stools per day and moderate cramps, nausea or vomiting</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 07:57:43 +0100" MODIFIED_BY="[Empty name]">
<P>97 participants (66%) had positive stool cultures</P>
<P>Major pathogenic organisms: ETEC - 49 (33%), Shigella - 25 (17%), Salmonella - 6 (4%), Rotavirus - 5 (3%)</P>
<P>Data on pre- and post-treatment antibiotic sensitivities not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 07:58:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ericsson-1986">
<CHAR_METHODS MODIFIED="2008-10-04 07:57:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation not stated</P>
<P>Patients kept daily diary of symptoms and medication doses, and were observed daily at the clinic site</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:57:51 +0100" MODIFIED_BY="[Empty name]">
<P>134 US students attending summer school in Guadalajara, Mexico during the summer of 1983</P>
<P>Entry criteria: four or more unformed stools per 24 hours or three unformed stools per 8 hours; diarrhoea of no more than 48 hours' duration; at least one of: abdominal pain, cramps, nausea, vomiting, fever</P>
<P>Participants with a temperature above 38.9 centigrade or with frank blood in the stools were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:57:59 +0100" MODIFIED_BY="[Empty name]">
<P>Groups and initial doses:<BR/>1. BW942 C 20 mg orally and placebo TMP/SMX<BR/>2. TMP/SMX 160/800 mg orally plus placebo BW942C<BR/>3. Both active formulations as above<BR/>4. Both placebo as above</P>
<P>Subsequent doses:<BR/>1. BW924C 10 mg orally five times daily and one placebo morning and night for 3 days<BR/>2. TMP/SMX 160/800 mg orally twice daily and placebo BW942C five times daily for 3 days<BR/>3. Both active formulations as above<BR/>4. Both placebo formulations as above</P>
<P>All groups: no dietary restrictions. Other antidiarrhoeal agents were prohibited</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:58:03 +0100" MODIFIED_BY="[Empty name]">
<P>1. Time to last unformed stool<BR/>2. Passage of half or less than half the number of unformed stools in a given interval compared with the numbers passed in a corresponding pre-treatment interval<BR/>3. Relapse: recurrence of symptoms at least 24 hours after what was thought to be the last unformed stool<BR/>4. Failure: worsening clinically within or after the 3-day treatment period or diarrhoea persisting beyond day 5</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 07:58:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ericsson-1987">
<CHAR_METHODS MODIFIED="2008-10-04 07:57:22 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation not stated</P>
<P>Patients kept daily diary of symptoms and medication doses</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:57:17 +0100" MODIFIED_BY="[Empty name]">
<P>191 US students attending summer school in Guadalajara, Mexico during the summer of 1984</P>
<P>Entry criteria: four or more unformed stools pers 24 hours or three unformed stools per 8 hours; diarrhoea of no more than 72 hours' duration; at least one of: abdominal pain, cramps, nausea, vomiting, fever</P>
<P>Passage of frank blood or fever above 38.9 centigrade were exclusion criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:57:11 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment:<BR/>1. Ciprofloxacin 500 mg orally twice daily for 5 days<BR/>2. TMP/SMX 160/800 mg orally twice daily for 5 days</P>
<P>Comparison:<BR/>3. Placebo twice daily for 5 days</P>
<P>All groups: no specific dietary restrictions. Use of other antidiarrhoeal medication was prohibited</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:58:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Time to last unformed stool<BR/>2. Well: Total diarrhoeal index score (defined in text) less than 1 or 0<BR/>3. Improvement: Passage of half or less than half the number of unformed stools in a given interval compared with the number in a corresponding pretreatment interval; Total diarrhoeal index half or less than half the enrollment index<BR/>4. Relapse: rise in patients' diarrhoeal index 24 or more hours after passage of what appeared to be the last unformed stool<BR/>5. Failed: Diarrhoea worsened clinically within the 5 day treatment period; diarrhoea persisting beyond day 5 of the study</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 07:58:24 +0100" MODIFIED_BY="[Empty name]">
<P>Results of pretreatment stool cultures not presented</P>
<P>Pretreatment antibiotic sensitivity patterns not disclosed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 07:59:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ericsson-1990">
<CHAR_METHODS MODIFIED="2008-10-04 07:58:32 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation not stated</P>
<P>Patients kept daily diary of symptoms and medication doses. Intention to treat analysis performed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:58:34 +0100" MODIFIED_BY="[Empty name]">
<P>227 US students attending summer school in Guadalajara, Mexico</P>
<P>Entry criteria: three or more unformed stools pers 24 hours; diarrhoea of no more than 14 days' duration; at least one of: abdominal cramps, nausea, or vomiting</P>
<P>Patients with frankly bloody stools or temperature above 39 centigrade were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:59:04 +0100" MODIFIED_BY="[Empty name]">
<P>1. Single oral dose sulfamethoxazole 1600 mg/trimethoprim 320 mg<BR/>2. SMX/TMP 800/160 twice daily for 3 days<BR/>3. Loperamide hydrochloride orally, 4 mg given as a loading dose, and 2 mg after each loose bowel movement (daily dose not to exceed 16 mg/ day)<BR/>4. Combination SMX/TMP and loperamide as in 2. and 4. above<BR/>5. Placebo</P>
<P>The medications were reformulated into two different colour capsules. White capsules contained 80 mg Trimethoprim/ 400 mg sulfamethoxazole or placebo. Yellow capsules contained 2 mg of loperamide or placebo. All subjects received a loading dose of 4 white and 2 yellow capsules</P>
<P>All groups received advice about fluid replacement and dietary adjustments</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:58:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. Duration of diarrhoea: number of hours from enrollment to passage of last unformed stool<BR/>2. Treatment failure: Passing more than half the number of stools in a 24-hour period that qualified them for enrollment, so long as that number exceeded three</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 07:58:57 +0100" MODIFIED_BY="[Empty name]">
<P>90 participants (40%) had positive stool cultures</P>
<P>Major pathogenic organisms: ETEC - 46 (20%), Shigella - 18 (8%), Aeromonas - 8 (4%), Campylobacter - 7 (3%), Plesiomonas - 7 (3%), Salmonella - 2 (1%)</P>
<P>No pre- or post-treatment antibiotic sensitivities reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 07:59:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ericsson-1992">
<CHAR_METHODS MODIFIED="2008-10-04 07:59:17 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation not stated</P>
<P>Patients kept daily diary of symptoms and medication doses</P>
<P>Patients were seen daily at the clinic site. Intention to treat analysis used</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:59:20 +0100" MODIFIED_BY="[Empty name]">
<P>190 US students attending summer school in Guadalajara, Mexico during the summers of 1988 and 1989</P>
<P>Entry criteria: three or more unformed stools per 24 hour period; diarrhoea of no more than 14 days' duration; at least one of: abdominal cramps, nausea, vomiting, or fever</P>
<P>Patients with frankly bloody stools or temperature above 39 centigrade were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. TMP/SMX 160/800 twice daily for 6 doses<BR/>2. TMP/SMX 320/1600 single dose with remaining doses of placebo<BR/>3. TMP/SMX 320/1600 single dose then 160/800 for 5 doses</P>
<P>All groups: Open label loperamide 4 mg loading dose and 2 mg following each loose stool (not exceeding 16 mg /day)</P>
<P>Information regarding fluid replacement and dietary adjustments</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of diarrhoea: number of hours from enrollment to passage of the last unformed stool, followed by at least 24 hours free of all symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 07:59:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ericsson-1997">
<CHAR_METHODS MODIFIED="2008-10-04 07:59:36 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, single-blind, placebo-controlled trial</P>
<P>Randomisation was performed using a table of random numbers</P>
<P>Patients kept daily diary of symptoms and medication doses</P>
<P>The primary outcome parameter was determined by a blinded evaluator</P>
<P>Intention to treat analysis used</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>166 US students attending summer school in Guadalajara, Mexico during the summers of 1992-1994</P>
<P>Entry criteria: three or more unformed stools per 24 hours and at least one of: abdominal cramps, nausea, vomiting, or fever</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:59:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ofloxacin 400 mg orally single dose<BR/>2. Ofloxacin 200 mg orally twice daily for 3 days<BR/>3. Ofloxacin 400 mg orally single dose plus loperamide for up to 3 days (4 mg loading dose, followed by 2 mg after each loose stool to a maximum of 16 mg/24 hour period)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:59:43 +0100" MODIFIED_BY="[Empty name]">
<P>Time from initiation of treatment to passage of last unformed stool</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 08:00:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuschner-1995">
<CHAR_METHODS MODIFIED="2008-10-04 07:59:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation not stated</P>
<P>Patients kept a daily diary of symptoms and timing of medication doses</P>
<P>Patients were seen daily for at least 3 days and then on day 10</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:59:54 +0100" MODIFIED_BY="[Empty name]">
<P>79 US military personnel participating in a military exercise in Thailand during May 1993</P>
<P>Entry criteria: three or more liquid bowel movements per 24 hour period; or two liquid stools plus cramps, nausea, vomiting, or fever; diarrhoea of no more than 48 hours' duration</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:59:57 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Azithromycin 500 mg orally daily for three days</P>
<P>Comparison: Ciprofloxacin 500 mg orally daily for three days</P>
<P>Both groups: Doxycycline daily as malaria prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 08:00:00 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical cure: resolution of diarrhoea and all symptoms within 72 hours after taking first dose of study medication<BR/>2. Treatment failure: persistency of diarrhoea or any symptom for longer than 72 hours after treatment was initiated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 08:00:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mattila-1993">
<CHAR_METHODS MODIFIED="2008-10-04 08:00:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled study</P>
<P>Efficacy analysis based on assigned treatment, i.e. not per intention to treat</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 08:00:10 +0100" MODIFIED_BY="[Empty name]">
<P>106 Finnish tourists visiting Agadir, Morocco in 1989</P>
<P>Entry criteria: four or more unformed stools per 24 hours or three unformed stools per 8 hours; at least one of: abdominal pain or spasms, nausea, vomiting, fever</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 08:00:13 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Norfloxacin 400 mg by mouth twice daily for three days</P>
<P>Control: Identical-looking placebo twice daily for three days</P>
<P>Both groups: No specific dietary restrictions, use of other antidiarrhoeal medication was prohibited, oral rehydration solution provided if required</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 08:00:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. Duration of diarrhoea: time to the passage of last unformed stool<BR/>2. Full recovery: cessation of all symptoms and signs by the fourth day after beginning treatment<BR/>3. Treatment failure: passage of at least one unformed stool during the day after the treatment period or deterioration on treatment<BR/>4. Relapse: diarrhea recurring at least 24 hours after the 3-day treatment period and after apparent recovery<BR/>5. Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 08:00:24 +0100" MODIFIED_BY="[Empty name]">
<P>This study spanned two seasons, namely Jan - February (winter) and October - November (fall)</P>
<P>67 participants (63%) had positive stool cultures, 21 cases with more than one pathogen</P>
<P>Major pathogenic organisms: ETEC - 27 (25%), Salmonella - 23 (22%), Campylobacter - 22 (21%), Aeromonas - 9 (8%), EPEC - 6 (6%), Rotavirus - 3 (3%), Shigella - 2 (2%)</P>
<P>100% of pretreatment stools sensitive to norfloxacin</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 08:00:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Petrucelli-1992">
<CHAR_METHODS MODIFIED="2008-10-04 08:00:29 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation not stated</P>
<P>Patients kept daily diary of symptoms and medication doses</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 08:00:31 +0100" MODIFIED_BY="[Empty name]">
<P>142 US military personnel participating in a military exercise in Thailand during May 1990</P>
<P>Entry criteria: three or more liquid bowel movements per 24 hour period; or two liquid stools plus cramps, nausea, or vomiting; diarrhoea of no more than 4 days duration</P>
<P>Patients were excluded if they had grossly bloody stools or high fever (38.3 centigrade)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 08:00:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ciprofloxacin 750 mg orally plus placebo<BR/>2. Ciprofloxacin 750 mg plus loperamide 4 mg followed by 2 mg after each liquid bowel movement (maximum 16 mg/day)<BR/>3. Ciprofloxacin 500 mg twice daily for three days plus loperamide 4 mg followed by 2 mg after each liquid bowel movement (maximum 16 mg/day)</P>
<P>All groups: Daily doxycycline for malaria prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 08:00:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Duration of illness:<BR/>Last unformed stool<BR/>Last liquid stool<BR/>2. Complete recovery from all symptoms<BR/>3. Severity:<BR/>Cumulative number of liquid bowel movements at 24, 48, and 72 hours after enrollment<BR/>4. Number of loperamide caplets taken after the loading dose</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 08:35:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salam-1994">
<CHAR_METHODS MODIFIED="2008-10-04 08:00:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation not stated</P>
<P>Patients kept daily diary of symptoms and medication doses</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 08:00:53 +0100" MODIFIED_BY="[Empty name]">
<P>88 British marines on military exercises in Belize and within 8 weeks of arrival</P>
<P>Inclusion criteria: one or more unformed stools</P>
<P>Participants with blood in their stools, fever &gt; 38.5 centigrade, or volume depletion requiring intravenous fluid therapy were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 08:00:55 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Ciprofloxacin 500 mg orally as a single dose</P>
<P>Comparison: Identical placebo orally as a single dose</P>
<P>Both groups: Chloroquine weekly and proguanil daily for malaria prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 08:35:48 +0100" MODIFIED_BY="[Empty name]">
<P>1. Duration of illness:<BR/>Time to last liquid stool<BR/>Time to last unformed stool (semi-solid or soft)</P>
<P>2. Severity:<BR/>Cumulative numbers of liquid and unformed stools at 24, 48, and 72 hours after enrolment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 08:01:00 +0100" MODIFIED_BY="[Empty name]">
<P>Stool cultures were not obtained by investigators</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 08:01:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steffen-1993">
<CHAR_METHODS MODIFIED="2008-10-04 08:01:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Randomisation by computer-generated list</P>
<P>Patients were seen daily by a physician who also administered the dose of medication</P>
<P>Patients kept a daily diary of symptoms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 08:01:08 +0100" MODIFIED_BY="[Empty name]">
<P>195 hotel guests at a resort in The Gambia</P>
<P>Diarrhoea of less than 6 days duration defined as at least one watery stool; one soft stool with abdominal cramps, vomiting, or nausea</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 08:01:16 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment:<BR/>1. Fleroxacin 400 mg orally single dose day one, placebo day 2<BR/>2. Fleroxacin 400 mg orally for two days<BR/>Placebo:<BR/>3. Placebo orally for two days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 08:01:16 +0100" MODIFIED_BY="[Empty name]">
<P>Cure: Passage of a formed stool unless followed thereafter by unformed stool; no stools passed within 24 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 08:01:34 +0100" MODIFIED_BY="[Empty name]">
<P>44 participants excluded from efficacy analysis, but 190 analysed for safety</P>
<P>79 participants (52%) had positive stool cultures</P>
<P>Major pathogenic organisms: ETEC - 44 (29%), Salmonella - 12 (8%), Plesiomonas - 4 (3%), Aeromonas - 2 (1%)</P>
<P>Pre- and post-treatment antibiotic sensitivities not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 08:01:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taylor-1991">
<CHAR_METHODS MODIFIED="2008-10-04 08:01:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind trial</P>
<P>Method of randomisation not stated</P>
<P>Patients kept daily diary of symptoms, time and form of stool, and medication doses</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 08:01:42 +0100" MODIFIED_BY="[Empty name]">
<P>162 military personnel participating in field training exercises in Egypt from October to November 1989</P>
<P>Inclusion criteria were three or more liquid stools in 24 hours; or one or two liquid stools accompanied by abdominal cramps, or vomiting</P>
<P>Participants with fever &gt;38.3 degrees centigrade, grossly bloody diarrhoea, or diarrhoea for longer than 60 hours were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 08:01:43 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: Ciprofloxacin 500 mg by mouth twice daily for three days plus loperamide, 4 mg initial dose followed by 2 mg with each unformed stool (to a maximum of 16 mg per 24 hours)</P>
<P>Comparison: ciprofloxacin 500 mg by mouth twice daily for three days plus placebo, taken in the same manner as loperamide</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 08:01:49 +0100" MODIFIED_BY="[Empty name]">
<P>1. Improvement: 50% decrease in daily number of stools compared to the previous 24 hours<BR/>2. Recovery: Total relief from all symptoms<BR/>3. Length of time lost from duty</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 08:01:49 +0100" MODIFIED_BY="[Empty name]">
<P>First dose observed, subsequent doses self- administered</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 08:02:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thornton-1992">
<CHAR_METHODS MODIFIED="2008-10-04 08:01:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation not stated</P>
<P>Patients were seen daily in clinic and at follow-up visits at one and four weeks following onset of illness</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 08:01:58 +0100" MODIFIED_BY="[Empty name]">
<P>142 male military personnel participating in 1986 and 1987 UNITAS/WATC shipboard exercises or 1986 Blue Horizon land-based exercise</P>
<P>Entry criteria: four or more unformed stools per 24 hours or three unformed stools per 8 hours; diarrhoea of no more than 48 hours' duration; at least one other sign of gastrointestinal illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 08:02:00 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Norfloxacin 400 mg orally twice daily for 5 days</P>
<P>Comparison: TMP/SMX 160/800 orally twice daily for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 08:02:03 +0100" MODIFIED_BY="[Empty name]">
<P>1. Duration of post-treatment diarrhoea<BR/>2. Cure: resolution of diarrhoea after 5 days of treatment<BR/>3. Failure: continued diarrhoea after treatment<BR/>4. Non-evaluable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 08:02:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wistrom-1989">
<CHAR_METHODS MODIFIED="2008-10-04 08:02:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled multi-centre trial</P>
<P>Method of randomisation not stated</P>
<P>Patients kept daily diary of symptoms, signs, and medication doses</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 08:02:09 +0100" MODIFIED_BY="[Empty name]">
<P>447 Swedish travellers on short duration trips (1-6 weeks) to developing countries who visited three participating travel clinics for pre-travel immunisations between December 1986 and April 1988</P>
<P>Entry criteria: four or more loose stools per 24 hours; two loose stools/24 hours plus any of the following: abdominal cramps, nausea, vomiting, or fever (&gt; 38 centigrade rectal temperature)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 08:02:14 +0100" MODIFIED_BY="[Empty name]">
<P>Self treatment</P>
<P>Treatment: Norfloxacin 400 mg twice daily orally for three days</P>
<P>Comparison: Identical placebo twice daily orally for three days</P>
<P>Both: Written and verbal instructions regarding the conduct of the trial. Sealed envelopes containing the randomisation code to be opened in the event of a medical emergency and returned to the investigators if not opened</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 08:02:21 +0100" MODIFIED_BY="[Empty name]">
<P>1. Cure: one or fewer loose stools per 24 hours without additional symptoms<BR/>Improving: two or three loose stools/24 hours without additional symptoms; one loose stool/24 hours with accompanying symptoms<BR/>2. Recurrence: return to inclusion criteria within 7 days after the last treatment dose<BR/>3. Failed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 08:02:23 +0100" MODIFIED_BY="[Empty name]">
<P>24 participants excluded initially</P>
<P>106 travellers developed diarrhoea meeting entry criteria</P>
<P>12 pathogens isolated on post-travel stool cultures</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-04 08:02:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wistrom-1992">
<CHAR_METHODS MODIFIED="2008-10-04 08:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
<P>Method of randomisation not stated</P>
<P>Patients kept a daily diary of symptoms and timing of medication doses</P>
<P>Patients were seen daily for at least 3 days and then on day 10</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 08:02:29 +0100" MODIFIED_BY="[Empty name]">
<P>42 US volunteers taken to a hotel in Puerto Vallarta, Mexico for 11 days</P>
<P>Entry criteria: four or more unformed stools in a 24 hour period; two loose stools in a 24 hour period plus any of: abdominal cramps, vomiting, fever &gt; 38 centigrade oral temperature</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 08:02:32 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Ciprofloxacin 250 mg twice daily orally for three days</P>
<P>Comparison: Placebo twice daily for three days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 08:02:37 +0100" MODIFIED_BY="[Empty name]">
<P>1. Cure: one or fewer loose stools per 24 hours without additional symptoms<BR/>Improving: two or three loose stools/24 hours without additional symptoms; one loose stool/24 hours with accompanying symptoms<BR/>2. Failed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 08:02:40 +0100" MODIFIED_BY="[Empty name]">
<P>17 participants developed diarrhoea</P>
<P>Major pathogenic organism: ETEC - 7 (41%)</P>
<P>100% of pretreatment stools sensitive to ciprofloxacin</P>
<P>ETEC found with in vitro resistance on pretreatment stools: Ampicillin - 63%, Doxycycline - 47%, chloramphenicol - 32%, SMX/TMP 17%</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ETEC, enterotoxigenic Escherichia coli; TMP, trimethoprim; SMX, sulfamethoxazole.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-10-04 08:03:55 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-10-04 08:03:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bouree-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-04 08:03:11 +0100" MODIFIED_BY="[Empty name]">
<P>This was a study of prophylaxis not treatment of travellers' diarrhoea. In this double-blind, placebo-controlled study, 75 French adults participating in a car and motorcycle rally were randomised to nifuroxazide 400 mg per day or placebo as prophylaxis against travellers' diarrhoea</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-04 08:03:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chagnon-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-04 08:03:11 +0100" MODIFIED_BY="[Empty name]">
<P>This was a review article and not a clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-04 08:03:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hill-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-04 08:03:23 +0100" MODIFIED_BY="[Empty name]">
<P>This unblinded trial allocated in rotation patients with acute onset of diarrhoea to one of four treatment groups:<BR/>1. "Empiric treatment" with magnesium sulphate and chlorodyne<BR/>2. Oxytetracycline 500 mg loading dose followed by 250 mg 6-hourly for 5 days<BR/>3. Sulfonamide (phthalylsulfathiazole) 4 g five times daily plus oral streptomycin 1 g four times daily for 6 days<BR/>4. Sulfonamide alone - phthalylsulfathiazole 4 g five times daily for 6 days</P>
<P>No inclusion criteria for frequency of stools, stool consistency, or other symptoms were defined in the report. Allocation was done before obtaining culture results. Results for patients with dysentery were considered separately to those with no identified pathogens</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-04 08:03:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Richards-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-04 08:03:26 +0100" MODIFIED_BY="[Empty name]">
<P>This study was a single-blind, non-randomised, placebo-controlled trial of prophylaxis with cloquinol 250 mg by mouth three or four times daily. The participants were British footballers playing abroad in the off season</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-04 08:03:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steffen-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-04 08:03:55 +0100" MODIFIED_BY="[Empty name]">
<P>This was a randomised, double-blind, placebo-controlled study of self-treatment of travellers' diarrhoea. The 2580 participants were Swiss residents visiting the Zurich University Vaccination Centre before travel to developing countries between July 1984 and December 1986. They were randomised, with stratification by destination, to one of seven regimens:<BR/>1. Bismuth subsalicylate 262.5 mg, 2 every 30 mins (total 8 doses per 24 hours)<BR/>2. Doxycycline 100 mg twice daily<BR/>3. Loperamide 4 mg loading dose and 2 mg after each unformed stool (max 16 mg per 24 hours)<BR/>4. Mecillinam 400 mg three times daily<BR/>5. Streptococcus faecium 75 x 10E6 SF68 three times daily<BR/>6. Trimethoprim/sulfamethoxazole 160/800 mg twice daily<BR/>7. Placebo</P>
<P>Participants were instructed to commence self-treatment with the development of any of the following symptoms: at least one watery stool; a pasty stool accompanied by cramps, nausea, vomiting, or fever</P>
<P>In this study, 482 participants were considered drop outs (18.9%) prior to travel. Of the 2098 who travelled, 798 developed diarrhoea, and 654 took the study medication (82% of eligible participants), but a further 115 were excluded for protocol violations, 35 for taking concurrent medications, and 17 for unspecified reasons. A total of 530 participants were analysed for drug efficacy (66% of eligible participants). Because of the high drop out rate the trial was excluded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-10-04 07:55:29 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2008-10-04 07:55:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1995">
<CHAR_METHODS MODIFIED="2008-10-04 07:55:21 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:55:21 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:55:21 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:55:21 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 07:55:21 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-04 07:55:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruns-1995">
<CHAR_METHODS MODIFIED="2008-10-04 07:55:25 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:55:25 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:55:25 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:55:25 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 07:55:25 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-04 07:55:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DuPont-1994">
<CHAR_METHODS MODIFIED="2008-10-04 07:55:29 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:55:29 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:55:29 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:55:29 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 07:55:29 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-04 07:55:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DuPont-1994b">
<CHAR_METHODS MODIFIED="2008-10-04 07:55:13 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:55:13 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:55:13 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:55:13 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 07:55:13 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-04 07:55:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DuPont-1997">
<CHAR_METHODS MODIFIED="2008-10-04 07:55:09 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:55:09 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:55:09 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:55:09 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 07:55:09 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-04 07:55:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ziegenhagen-1992">
<CHAR_METHODS MODIFIED="2008-10-04 07:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 07:55:00 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-04 07:55:02 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-04 07:55:03 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-04 07:55:04 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-11 14:16:03 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-08-11 14:16:03 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-04 07:54:45 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-10-04 07:54:45 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Duration of post-treatment diarrhoea (hours)</TITLE>
<TABLE COLS="8" ROWS="7">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="3" VALIGN="BOTTOM">
<P>Treatment</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="3" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Pooled SD</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>N</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Mean</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>SD</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>N</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Mean</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>SD</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-DuPont-1992b" TYPE="STUDY">DuPont 1992b</LINK> (Ofloxacin 3-days)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>81</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>79</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>56</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>48</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-DuPont-1992b" TYPE="STUDY">DuPont 1992b</LINK> (Ofloxacin 5-days)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>66</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>79</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>56</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>48</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ericsson-1983" TYPE="STUDY">Ericsson 1983</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28.2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27.3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63.7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46.1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Salam-1994" TYPE="STUDY">Salam 1994</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>45</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24.8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25.49</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>38</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>53.5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27.12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wistrom-1992" TYPE="STUDY">Wistrom 1992</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27.989</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Antibiotic versus placebo</NAME>
<DICH_OUTCOME CHI2="6.83102440418855" CI_END="8.566919041484136" CI_START="4.0593758449536255" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="5.897147125744274" ESTIMABLE="YES" EVENTS_1="330" EVENTS_2="154" I2="26.80453612588222" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.9328246627800535" LOG_CI_START="0.6084592631509439" LOG_EFFECT_SIZE="0.7706419629654986" METHOD="MH" NO="1" P_CHI2="0.23351367310946514" P_Q="1.0" P_Z="1.2410572684944983E-20" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="391" TOTAL_2="306" WEIGHT="100.00000000000003" Z="9.313141870956064">
<NAME>Number cured at 72 hours</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="35.64526558533477" CI_START="5.465945231296126" EFFECT_SIZE="13.958333333333334" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="18" LOG_CI_END="1.552001854897393" LOG_CI_START="0.7376652757530854" LOG_EFFECT_SIZE="1.1448335653252393" ORDER="303" O_E="0.0" SE="0.4783453376204447" STUDY_ID="STD-DuPont-1982" TOTAL_1="75" TOTAL_2="48" VAR="0.22881426202321722" WEIGHT="10.012612164708695"/>
<DICH_DATA CI_END="32.27796722140044" CI_START="3.4311506091373665" EFFECT_SIZE="10.523809523809524" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="42" LOG_CI_END="1.5089061762257738" LOG_CI_START="0.5354397816766092" LOG_EFFECT_SIZE="1.0221729789511915" ORDER="304" O_E="0.0" SE="0.5718189788945479" STUDY_ID="STD-Ericsson-1983" TOTAL_1="72" TOTAL_2="68" VAR="0.3269769446240034" WEIGHT="10.262927468826412"/>
<DICH_DATA CI_END="7.477178842061105" CI_START="1.4911763241198632" EFFECT_SIZE="3.3391304347826085" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="23" LOG_CI_END="0.8737377683946252" LOG_CI_START="0.17352899963321297" LOG_EFFECT_SIZE="0.5236333840139191" ORDER="305" O_E="0.0" SE="0.4113060968597593" STUDY_ID="STD-Mattila-1993" TOTAL_1="51" TOTAL_2="55" VAR="0.16917270531400966" WEIGHT="27.835770257430127"/>
<DICH_DATA CI_END="28.916496521626797" CI_START="1.1367598106681644" EFFECT_SIZE="5.733333333333333" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="30" LOG_CI_END="1.4611456733564132" LOG_CI_START="0.055668711019359794" LOG_EFFECT_SIZE="0.7584071921878864" ORDER="306" O_E="0.0" SE="0.8255841248999534" STUDY_ID="STD-Salam-1994" TOTAL_1="45" TOTAL_2="38" VAR="0.6815891472868217" WEIGHT="6.182486427003863"/>
<DICH_DATA CI_END="9.754138772328561" CI_START="2.202266169393401" EFFECT_SIZE="4.6347826086956525" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="23" LOG_CI_END="0.9891889300158321" LOG_CI_START="0.342869807330089" LOG_EFFECT_SIZE="0.6660293686729606" ORDER="307" O_E="0.0" SE="0.37965105199686094" STUDY_ID="STD-Steffen-1993" TOTAL_1="102" TOTAL_2="49" VAR="0.1441349212823232" WEIGHT="26.053789380022902"/>
<DICH_DATA CI_END="11.385895147387842" CI_START="1.9585094037305724" EFFECT_SIZE="4.722222222222222" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" LOG_CI_END="1.0563671800797316" LOG_CI_START="0.2919256611422417" LOG_EFFECT_SIZE="0.6741464206109866" ORDER="308" O_E="0.0" SE="0.44903673227042856" STUDY_ID="STD-Wistrom-1989" TOTAL_1="46" TOTAL_2="48" VAR="0.20163398692810455" WEIGHT="19.652414302008026"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="17.390091792539057" CI_END="-0.9299068820035427" CI_START="-1.6263774407037812" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2781421613536619" ESTIMABLE="YES" I2="65.49759442572807" I2_Q="82.07508366687297" ID="CMP-001.02" NO="2" P_CHI2="0.0079516280470745" P_Q="8.006404399788503E-4" P_Z="6.304211986724895E-13" Q="16.736479792966733" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="396" TOTAL_2="356" UNITS="" WEIGHT="400.0" Z="7.193735821512487">
<NAME>Severity (number of unformed stools / 24 hour period)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6055684087998436" CI_START="-0.8055684087998438" DF="0" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="0.7811773218997169" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="38" WEIGHT="100.0" Z="0.2777851105711934">
<NAME>Baseline</NAME>
<CONT_DATA CI_END="0.6055684087998436" CI_START="-0.8055684087998438" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.1" ORDER="309" SD_1="2.01" SD_2="1.23" SE="0.35999049695059565" STUDY_ID="STD-Ericsson-1983" TOTAL_1="45" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5344744387114184" CI_END="-0.5205046211899302" CI_START="-2.6648867900252053" DF="1" EFFECT_SIZE="-1.5926957056075677" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.4647318431366281" P_Z="0.0035976032608819888" STUDIES="2" TAU2="0.0" TOTAL_1="117" TOTAL_2="106" WEIGHT="100.0" Z="2.9114457923495594">
<NAME>0 - 24 hours</NAME>
<CONT_DATA CI_END="0.3026494978936123" CI_START="-2.7026494978936126" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="5.8" ORDER="310" SD_1="3.7" SD_2="5.2" SE="0.7666719948663955" STUDY_ID="STD-Ericsson-1983" TOTAL_1="72" TOTAL_2="68" WEIGHT="50.913036799054055"/>
<CONT_DATA CI_END="-0.4696558450233532" CI_START="-3.530344154976647" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="5.8" ORDER="311" SD_1="3.35" SD_2="3.7" SE="0.7808021815950732" STUDY_ID="STD-Salam-1994" TOTAL_1="45" TOTAL_2="38" WEIGHT="49.086963200945945"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.878209815253983E-31" CI_END="-1.4171902065010822" CI_START="-2.782809793498917" DF="1" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" NO="3" P_CHI2="0.9999999999999993" P_Z="1.660808759366404E-9" STUDIES="2" TAU2="0.0" TOTAL_1="117" TOTAL_2="106" WEIGHT="100.0" Z="6.027922280439052">
<NAME>25 - 48 hours</NAME>
<CONT_DATA CI_END="-1.1486838041311647" CI_START="-3.051316195868835" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="3.3" ORDER="312" SD_1="1.8" SD_2="3.6" SE="0.4853743249226494" STUDY_ID="STD-Ericsson-1983" TOTAL_1="72" TOTAL_2="68" WEIGHT="51.51689766252129"/>
<CONT_DATA CI_END="-1.1193714329143984" CI_START="-3.0806285670856015" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="3.2" ORDER="313" SD_1="2.01" SD_2="2.47" SE="0.5003298911718147" STUDY_ID="STD-Salam-1994" TOTAL_1="45" TOTAL_2="38" WEIGHT="48.48310233747871"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.11913756086089757" CI_END="-0.8235518241315306" CI_START="-1.9376342876214476" DF="1" EFFECT_SIZE="-1.3805930558764892" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" NO="4" P_CHI2="0.7299718190038544" P_Z="1.187857134820965E-6" STUDIES="2" TAU2="0.0" TOTAL_1="117" TOTAL_2="106" WEIGHT="100.0" Z="4.857652383015906">
<NAME>49 - 72 hours</NAME>
<CONT_DATA CI_END="-0.57907921265695" CI_START="-2.0209207873430497" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.9" ORDER="314" SD_1="1.2" SD_2="2.8" SE="0.36782348707914075" STUDY_ID="STD-Ericsson-1983" TOTAL_1="72" TOTAL_2="68" WEIGHT="59.703472061755306"/>
<CONT_DATA CI_END="-0.6224870615294069" CI_START="-2.377512938470593" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="2.0" ORDER="315" SD_1="1.34" SD_2="2.47" SE="0.4477189098331924" STUDY_ID="STD-Salam-1994" TOTAL_1="45" TOTAL_2="38" WEIGHT="40.29652793824469"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.8104163597336402" CI_END="3.746306494640933" CI_START="1.5017498052467055" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="2.3719222265330475" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.5736033052031682" LOG_CI_START="0.17659758429824313" LOG_EFFECT_SIZE="0.3751004447507057" METHOD="MH" NO="3" P_CHI2="0.5900360388498405" P_Q="1.0" P_Z="2.125268407749857E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="523" TOTAL_2="339" WEIGHT="100.0" Z="3.7036411496568893">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="35.974735877480896" CI_START="0.056805325923988494" EFFECT_SIZE="1.429530201342282" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5559976140784504" LOG_CI_START="-1.245610944025523" LOG_EFFECT_SIZE="0.1551933350264637" ORDER="316" O_E="0.0" SE="1.6456787352162998" STUDY_ID="STD-DuPont-1982" TOTAL_1="75" TOTAL_2="35" VAR="2.70825849954312" WEIGHT="2.6696379025919583"/>
<DICH_DATA CI_END="3.3567390081991775" CI_START="0.6871554675135274" EFFECT_SIZE="1.51875" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" LOG_CI_END="0.5259175754734305" LOG_CI_START="-0.16294499358865575" LOG_EFFECT_SIZE="0.1814862909423874" ORDER="317" O_E="0.0" SE="0.4046412829917809" STUDY_ID="STD-DuPont-1992" TOTAL_1="98" TOTAL_2="93" VAR="0.16373456790123456" WEIGHT="40.34428016257597"/>
<DICH_DATA CI_END="145.38175443624965" CI_START="0.4620413916415568" EFFECT_SIZE="8.195876288659793" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.1625099055266843" LOG_CI_START="-0.3353191167462331" LOG_EFFECT_SIZE="0.9135953943902254" ORDER="318" O_E="0.0" SE="1.4672371321361832" STUDY_ID="STD-DuPont-1992b" TOTAL_1="152" TOTAL_2="79" VAR="2.1527848019192115" WEIGHT="2.5062314866283697"/>
<DICH_DATA CI_END="51.98291639655227" CI_START="0.7136801111870588" EFFECT_SIZE="6.090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.7158606410634107" LOG_CI_START="-0.146496405978208" LOG_EFFECT_SIZE="0.7846821175426014" ORDER="319" O_E="0.0" SE="1.093957748248309" STUDY_ID="STD-Ericsson-1983" TOTAL_1="72" TOTAL_2="68" VAR="1.1967435549525103" WEIGHT="3.784077349177326"/>
<DICH_DATA CI_END="4.701114596734555" CI_START="1.36695774326874" EFFECT_SIZE="2.535" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="25" LOG_CI_END="0.6722008378980723" LOG_CI_START="0.13575508944063727" LOG_EFFECT_SIZE="0.4039779636693548" ORDER="320" O_E="0.0" SE="0.3151108880931787" STUDY_ID="STD-Steffen-1993" TOTAL_1="126" TOTAL_2="64" VAR="0.09929487179487179" WEIGHT="50.69577309902638"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>